Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Clinical trial NCT02996825 · COMPLETED

Trial details

NCT number: NCT02996825
Sponsor: City of Hope Medical Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Breast Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma Triple-Negative Breast Carcinoma

Start date: 2017-03-22
Primary completion: 2024-02-09
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.